Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New GPR119 receptor agonists presented by Taisho Pharmaceutical

Jan. 15, 2013

MSD suspends availability of Tredaptive

Jan. 14, 2013

Esperion's ETC-1002 lowers LDL cholesterol in phase II trial

Jan. 14, 2013

Ultragenyx inlicenses triheptanoin from Baylor Research Institute

Jan. 14, 2013

Metabolex presents new GPBA receptor agonists

Jan. 14, 2013

FDA advisory committee recommends approval of canagliflozin

Jan. 11, 2013

Oramed submits IND application for phase II trial of oral insulin candidate

Jan. 11, 2013

SK Biopharmaceuticals divulges new 1-beta-HSD1 inhibitors

Jan. 11, 2013

Novel 11-beta-HSD1 inhibitor with potential for treating diabetes identified at Pfizer

Jan. 11, 2013

Bayer's Skyla approved by FDA to prevent pregnancy for up to 3 years

Jan. 10, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...